[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-glioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-glioma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100482011","phase-1-f-tryptophan-petct-in-human-cancers-100482011",false,"NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers","A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET\u002FCT Imaging In Human Cancers","Inclusion Criteria:\n\n* Age ≥18 years.\n* Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.\n* Patient is able to lie in the PET\u002FCT scanner for at least 70 minutes while undergoing scanning.\n* Women of childbearing potential must not be pregnant or breastfeeding.\n* Recent anatomic imaging with visible disease (tumor) for comparison with the PET\u002FCT. .\n* Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.\n* Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.\n\nInclusion Criteria Specific for Intracranial Tumors\n\n\\- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.\n\nInclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.\n* ECOG performance status of 2 or better.\n* Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \\[LAR\\], depot) for \\>3 months before enrollment may be enrolled on the study, but such treatment is not required.\n\nInclusion Criteria specific for Extracranial Primary Breast tumors:\n\n* Clinical and radiological diagnosis of a breast cancer\n* ECOG performance status of 2 or better.\n\nInclusion Criteria specific for Rectal tumors:\n\n* Histologically confirmed colorectal cancer, which is located in the rectum.\n* ECOG performance status of 2 or better.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating are excluded.\n\nExclusion Criteria Specific for Intracranial Tumors:\n\n* Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.\n* Tumor surgery or radiation within 1 month prior to the PET scan\n\nExclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Tumor-directed therapy within 3 months to the area of planned imaging.\n* Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).\n* Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.\n\nExclusion Criteria for Extracranial Primary Breast tumors:\n\n-Recent (within 1 month) tumor resection or radio-chemotherapy (acute\u002Fsubacute post-treatment inflammatory changes may cause false positive increases on PET).\n\nExclusion Criteria for Rectal tumors:\n\n-Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Imaging procedures such as 1-(2-\\[18F\\]FLUOROETHYL)-L-Tryptophan PET\u002FCT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.",[26,27,28,29,30],"Intracranial Glioma","Metastatic Brain Tumor","Breast Cancer","Neuroendocrine Tumors","Rectal Cancer","RECRUITING","2026-01-21",{"date":34,"type":35},"2026-01-23","ACTUAL",{"date":37,"type":35},"2022-09-29",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Barbara Ann Karmanos Cancer Institute","OTHER"]